China Medical Technologies (Ticker: CMED)
Company Profile and Private Investigations

Company Profile:

China Medical Technologies is a company in the health care industry. China Medical Technologies' HIFU therapy system treats solid tumor cancers and benign tumors using linear ultrasound waves to raise the temperature of the targeted tumor tissue. The system is used primarily to treat liver, lung, breast, prostate, and kidney cancers, along with tumors in arms and legs and superficial tissues. Its ECLIA system is a luminescence immunoassay diagnostic system used to detect thyroid disorders, diabetes, reproductive disorders, SARS, and tumor markers. China Medical Technologies offers 27 reagent kits for use with the ECLIA system. Founder and CEO Xiaodong Wu owns about 55% of the company, which operates through subsidiary YDME Beijing.

China Medical Technologies' website describes the company as follows:

Beijing Yuande Bio-Medical Engineering Co.,Ltd. is a high-tech enterprise engaged in the R&D and production of large-scale medical equipments, instruments and reagents. At present, major shareholders of the company include Chengxuan International Company, Golden Meditech Co.,Ltd. and GE Healthcare Group. The company was founded in 1999 and located at Beijing Economical & Technological Development Zone. We passed the International Quality System Certification of ISO9001 in 2001.

Cooperated with researchers from Peking University, we have developed High Intensity Focused Ultrasound (HIFU) tumor therapy system through years of efforts with considerable investments. The equipment was granted the register and manufacture license by State Drug Administration in 1999. Moreover, this project has been listed as a State High-Tech Industrialization Advanced Project and approved by Science Research Fund of the Ministry of Public Health. The success in clinical application of High Intensity Focused Ultrasound tumor therapy system has realized the dream of non-invasive treatment of tumor. The product has got many patents both in China and abroad. Having been evaluated and demonstrated by senior experts for many times, the clinical application of this technology is considered to have reached world leading level.

Through efforts on the research of chemiluminescence analysis, we are the first China-based company to grasp the core technology thereof, and the first to have a platform to develop and manufacture both equipment and reagent. We launched of our Enhanced Chemiluminescence Immunoassay (ECLIA) analysis system and reagents in 2004.

We have a modern factory to produce High Intensity Focused Ultrasound tumor therapy system, ECLIA system and reagents and to carry out the R&D of new products. Our company is managed by experienced professional team and talented scientists. We have established nation-wide sale and customer service network. Sustained technical innovation, strict quality control and comprehensive after-sales service constitute our core competence, and create a solid foundation for our healthy growth.

The name and description sound good.  But how is the company?  Please see

Our Private Investigations:

On August 22, 2005, we tried several times to dial the phone numbers of China Medical Technologies, or Beijing Yuande Bio-Medical Engineering Co.,Ltd.

The phone number we tried was (86 10) 67871166, which was listed on the company's website at http://www.yuande.com/cus.html . Unfortunately, no one answered the phone call. 

Although its name sounds big and powerful, our associate who is currently in medical equipment supplies industry has never heard of China Medical Technologies, and the company currently only has two products.  How are these two products?  For details, please see our China Investment Report